EW stock forecast: what analysts expect
Wall Street analysts covering Edwards Lifesciences Corporation currently rate the stock a Buy on average, with a mean 12-month price target of $100.96 — +8.5% versus the last price of $93.05. Targets reflect analyst opinion, not a guarantee.
EW historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in EW.
EW annual returns by year
Congress trading in EW
10 members of Congress have disclosed trading EW — 5 purchases and 11 sales worth an estimated $152,500. Most recent disclosure: Nov 19, 2025.
See who in Congress traded EW →Insider activity in EW
EW's own executives and directors have made 0 open-market purchases ($0) and 13 sales ($5.0M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 11, 2026.
| Aug 11, 2026 | Lippis Daniel J. | CVP, TAVR | Sell | $56,967 |
| Jul 30, 2026 | Markowitz Wayne | CVP, JAPAC | Sell | $12,588 |
| Jul 28, 2026 | Markowitz Wayne | CVP, JAPAC | Sell | $818,958 |
| Jul 27, 2026 | Zovighian Bernard J | CEO | Sell | $245,134 |
| Jul 10, 2026 | Lippis Daniel J. | CVP, TAVR | Sell | $56,762 |
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Key Statistics
EW in plain English
- P/E ratio (55.7) — how many dollars you pay for each $1 of EW's yearly profit. That's high, so the market expects strong growth (and you're paying up for it).
- ROE (9.18%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
- Profit margin (15.43%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — EW doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
EW stock: frequently asked questions
What is Edwards Lifesciences Corporation's stock price today?
Edwards Lifesciences Corporation (EW) last traded at $93.05 on the NYSE. Over the past 52 weeks the stock has traded between $72.30 and $96.29.
Is EW stock a buy or a sell?
Wall Street analysts' consensus rating on EW is "Buy", with an average 12-month price target of $100.96 — about +8.5% versus the current price of $93.05. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in EW 10 years ago be worth today?
A $1,000 investment in Edwards Lifesciences Corporation made 10 years ago would be worth about $2,424 today (dividends reinvested) — a total return of 142%, or 9.3% per year.
Does EW pay a dividend?
No — Edwards Lifesciences Corporation does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is EW's P/E ratio?
EW trades at a trailing price-to-earnings ratio of 55.7, and 27.6 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade EW stock?
Yes — 10 members of Congress have disclosed trades in EW under the STOCK Act, totaling 5 purchases and 11 sales worth an estimated $152,500.
What is Edwards Lifesciences Corporation's ticker symbol?
Edwards Lifesciences Corporation trades under the ticker symbol EW on the NYSE.
Compare EW with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.